Relative expression of CD164 epitopes on CD34CD38 subsets of human fetal liver CD34+ cells
| Cell Fraction . | Median Fluorescence Intensities of CD164 or Isotype Control-Labeled Fractions (mean ± SD; n = 3) . | ||||||
|---|---|---|---|---|---|---|---|
| CD34CD38 Subset . | % Cells Per Fraction . | Class I 105A5 . | mIgM . | Class II 103B2/9E10 . | mIgG3 . | Class III N6B6 . | mIgG2a . |
| CD34hiCD38lo (R2) | 8 ± 2% | 44 ± 21 | 4 ± 1 | 416 ± 226 | 3 ± 1 | 311 ± 164 | 3 ± 1 |
| CD34++CD38+(R3) | 48 ± 3% | 37 ± 19 | 4 ± 1 | 324 ± 212 | 3 ± 1 | 249 ± 161 | 4 ± 1 |
| CD34++CD38++ (R4) | 31 ± 2% | 24 ± 8 | 4 ± 0 | 148 ± 57 | 4 ± 1 | 143 ± 50 | 5 ± 1 |
| CD34+CD38+++(R5) | 9 ± 6% | 6 ± 2 | 2 ± 0 | 8 ± 1 | 2 ± 0 | 15 ± 3 | 5 ± 1 |
| Cell Fraction . | Median Fluorescence Intensities of CD164 or Isotype Control-Labeled Fractions (mean ± SD; n = 3) . | ||||||
|---|---|---|---|---|---|---|---|
| CD34CD38 Subset . | % Cells Per Fraction . | Class I 105A5 . | mIgM . | Class II 103B2/9E10 . | mIgG3 . | Class III N6B6 . | mIgG2a . |
| CD34hiCD38lo (R2) | 8 ± 2% | 44 ± 21 | 4 ± 1 | 416 ± 226 | 3 ± 1 | 311 ± 164 | 3 ± 1 |
| CD34++CD38+(R3) | 48 ± 3% | 37 ± 19 | 4 ± 1 | 324 ± 212 | 3 ± 1 | 249 ± 161 | 4 ± 1 |
| CD34++CD38++ (R4) | 31 ± 2% | 24 ± 8 | 4 ± 0 | 148 ± 57 | 4 ± 1 | 143 ± 50 | 5 ± 1 |
| CD34+CD38+++(R5) | 9 ± 6% | 6 ± 2 | 2 ± 0 | 8 ± 1 | 2 ± 0 | 15 ± 3 | 5 ± 1 |
Purified CD34+ cells from fetal liver cells were labeled with CD34-PerCP, CD38-APC, AC133-PE, and the different CD164 MAbs plus FITC-conjugated anti-isotype secondary antibodies (mIgM, mIgG3, mIgG2a) as described in “Materials and methods.” The fluorescence gates (R2 to R5) are described in the dot plots shown in Figure 3. The percentages of cells falling within each gate were determined by comparison with the negative isotype-matched control MAbs. Median fluorescence intensities were determined for CD164 epitope labeling after gating cells for relative levels of CD34 and CD38 expression. Values represent means ± SD of 3 independent experiments.